Compare Becton Dickinson and Co (BDX) vs Live Nation Entertainment, Inc. (LYV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Live Nation Entertainment, Inc. — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Live Nation Entertainment, Inc. trades at $180.84 (market cap $42.25B). The key difference: Becton Dickinson and Co and Live Nation Entertainment, Inc. are close in size by market cap, and Becton Dickinson and Co pays a 2.79% dividend while Live Nation Entertainment, Inc. pays none. Which is the better fit depends on your goals.
| BDX | LYV | |
|---|---|---|
Market Cap | $41.51B | $42.25B |
Sector | Health | Industrials |
52-Week High | $185.39 | $186.59 |
52-Week Low | $135.49 | $125.61 |
Enterprise Value | $57.97B | $43.76B |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Live Nation (LYV) trades at $183.25, up 1.92% with strong analyst support (88.6% buy ratings) and a $200.20 consensus target. The stock shows bullish technical signals with support at $178 and resistance at $185. Despite recent earnings misses, revenue grew to $25.2B in 2025, though net margins remain thin at 0.33% with negative ROE of -24.68%.
The outlook remains positive given strong concert demand and ticketing dominance, but elevated valuation (P/E 117.5) and regulatory scrutiny pose risks. Cash flow improved to $1.0B net in 2025, supporting growth investments. Institutional sentiment favors upside to price targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →
